No price relief in India for GSK's "innovative"analgesic
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's hopes of getting the fast- acting version of its analgesic/antipyretic, Crocin, out of price control in India appear to have been dashed, with the country's price regulator rejecting the UK-based multinational's application.